At Myllia, our mission is to accelerate drug discovery through high-content CRISPR screening. Since our founding in 2018 by Thomas Moser (CEO), Tilmann Buerckstuemmer (CSO), and Christoph Bock (Scientific Advisor), we have partnered with biotech and pharmaceutical companies globally to support their drug discovery programmes.
We are committed to identifying and validating drug targets through CRISPR screening in the most biologically relevant cellular models: - 150+ CRISPR screens in cell lines and primary human cells - 35+ collaborative projects worldwide - End-to-end workflows from experimental screening to computational analysis
Our platform integrates multiple CRISPR modalities with primary human cell types, combined with high-content readouts such as single-cell RNA-Seq, CITE-Seq, FACS, and fitness assays. 👇 Are you curious how functional genomics can transform drug discovery? Follow us for updates & insights, and check out www.myllia.com
🧬 Meet #TeamMyllia
Our mission is to accelerate drug discovery through high-content CRISPR screening:
- 150+ CRISPR screens in cell lines and primary cells
- 35+ collaborative projects worldwide
- End-to-end workflows from screening to bioinformatics
www.myllia.com
